Current Cardiovascular Risk Reports

, Volume 1, Issue 4, pp 303–309 | Cite as

Low-molecular-weight heparin use in acute coronary syndromes and percutaneous coronary interventions: An update

  • Jeffrey J. Link
  • John J. Warner
  • James A. de Lemos
Article
  • 16 Downloads

Abstract

Based on important studies published in the past year, the role of low-molecular-weight heparin in acute coronary syndromes and percutaneous coronary interventions has continued to evolve. For patients with non-ST-elevation acute coronary syndromes, several alternatives to enoxaparin have been introduced, including fondaparinux and bivalirudin. In patients with ST-elevation myocardial infarction, recent studies have demonstrated a clear mortality benefit from adjunctive antithrombin therapy and the superiority of a prolonged course of enoxaparin over a standard duration of unfractionated heparin. Furthermore, recent data have demonstrated the safety of enoxaparin as an alternative to unfractionated heparin among patients undergoing percutaneous coronary interventions.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Young E, Wells P, Holloway S, et al.: Ex-vivo and in-vitro evidence that low molecular weight heparins exhibit less binding to plasma proteins than unfractionated heparin. Thromb Haemost 1994, 71:300–304.PubMedGoogle Scholar
  2. 2.
    Salzman EW, Rosenberg RD, Smith MH, et al.: Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980, 65:64–73.PubMedCrossRefGoogle Scholar
  3. 3.
    Warkentin TE, Levine MN, Hirsh J, et al.: Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med 1995, 332:1330–1335.PubMedCrossRefGoogle Scholar
  4. 4.
    Ernofsson M, Strekerud F, Toss H, et al.: Low-molecular weight heparin reduces the generation and activity of thrombin in unstable coronary artery disease. Thromb Haemost 1998, 79:491–494.PubMedGoogle Scholar
  5. 5.
    Hansen JB, Naalsund T, Sandset PM, Svensson B: Rebound activation of coagulation after treatment with unfractionated heparin and not with low molecular weight heparin is associated with partial depletion of tissue factor pathway inhibitor and antithrombin. Thromb Res 2000, 100:413–417.PubMedCrossRefGoogle Scholar
  6. 6.
    Montalescot G, Philippe F, Ankri A, et al.: Early increase of von Willebrand factor predicts adverse outcome in unstable coronary artery disease: beneficial effects of enoxaparin. French Investigators of the ESSENCE Trial. Circulation 1998, 98:294–299.PubMedGoogle Scholar
  7. 7.
    Bijsterveld NR, Moons AH, Meijers JC, et al.: Rebound thrombin generation after heparin therapy in unstable angina. A randomized comparison between unfractionated and low-molecular-weight heparin. J Am Coll Cardiol 2002, 39:811–817.PubMedCrossRefGoogle Scholar
  8. 8.
    Cohen M, Demers C, Gurfinkel EP, et al.: A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. N Engl J Med 1997, 337:447–452.PubMedCrossRefGoogle Scholar
  9. 9.
    Antman EM, McCabe CH, Gurfinkel EP, et al: Enoxaparin prevents death and cardiac ischemic events in anstable angina/non-Q-wave myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIM) 11B trial. Circulation 1999, 100:1593–1601.PubMedGoogle Scholar
  10. 10.
    Antman EM, Cohen M, McCabe C, et al.: Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur Heart J 2002, 23:308–314.PubMedCrossRefGoogle Scholar
  11. 11.
    Braunwald E, Antman EM, Beasley JW, et al.: ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002, 40:1366–1374.PubMedCrossRefGoogle Scholar
  12. 12.
    Blazing MA, de Lemos JA, White HD, et al.: Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004, 292:55–64.PubMedCrossRefGoogle Scholar
  13. 13.
    de Lemos JA, Blazing MA, Wiviott SD, et al.: Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307–1316.PubMedCrossRefGoogle Scholar
  14. 14.
    Ferguson JJ, Califf RM, Antman EM, et al.: Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004, 292:45–54.PubMedCrossRefGoogle Scholar
  15. 15.
    Yusuf S, Mehta SR, Chrolavicius S, et al.: Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464–1476.PubMedCrossRefGoogle Scholar
  16. 16.
    Lincoff AM, Kleiman NS, Kereiakes DJ, et al.: Long-term efficacy of bivalirudin and provisional glycoprotein IIb/IIIa blockade vs heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary revascularization: REPLACE-2 randomized trial. JAMA 2004, 292:696–703.PubMedCrossRefGoogle Scholar
  17. 17.
    Cohen DJ, Lincoff AM, Lavelle TA, et al.: Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention: results from the REPLACE-2 trial. J Am Coll Cardiol 2004, 44:1792–1800.PubMedGoogle Scholar
  18. 18.
    Stone GW, McLaurin BT, Cox DA, et al.: Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203–2216.PubMedCrossRefGoogle Scholar
  19. 19.
    Antman EM, Anbe DT, Armstrong PW, et al.: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infraction—executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004, 44:671–719.PubMedCrossRefGoogle Scholar
  20. 20.
    Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 2001, 358:605–613.Google Scholar
  21. 21.
    Wallentin L, Goldstein P, Armstrong PW, et al.: Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 2003, 108:135–142.PubMedCrossRefGoogle Scholar
  22. 22.
    Yusuf S, Mehta SR, Xie C, et al.: Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005, 293:427–435.PubMedCrossRefGoogle Scholar
  23. 23.
    Antman EM, Morrow DA, McCabe CH, et al.: Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006, 354:1477–1488.PubMedCrossRefGoogle Scholar
  24. 24.
    Yusuf S, Mehta SR, Chrolavicius S, et al.: Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. JAMA 2006, 295:1519–1530.PubMedCrossRefGoogle Scholar
  25. 25.
    Montalescot G, White HD, Gallo R, et al.: Enoxaparin versus unfractionated heparin in elective percutaneous coronary intervention. N Engl J Med 2006, 355:1006–1017.PubMedCrossRefGoogle Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  • Jeffrey J. Link
  • John J. Warner
  • James A. de Lemos
    • 1
  1. 1.University of Texas Southwestern Medical CenterDallasUSA

Personalised recommendations